<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005770</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0408</org_study_id>
    <nct_id>NCT02005770</nct_id>
  </id_info>
  <brief_title>Anesthesia and Circulating Tumor Cells in Breast Cancer</brief_title>
  <official_title>Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serious concern about the role of anesthesia in tumor recurrence has considerably risen over
      years, but the lack of surrogate markers for tumor spreading made trials addressing this
      issue difficult to realize. In breast cancer patients CTC positivity has been recently
      recognized as an independent prognostic factor. In this respect, we postulated that in a
      first step changes in the number of CTC after general anesthesia would help to determine the
      effect of anesthesia on this tumor marker.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with primary breast cancer will be randomized to either propofol or sevoflurane
      anesthesia for curative surgery. CTC will be determined in the pre- as well as postoperative
      phase and the kinetic of CTC in the two groups will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CTC before and after administration of anesthetics</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Female Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General anesthesia using Sevoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General anesthesia using propofol TCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: &gt; Female

          -  Age 18 to 85

          -  ASA I-III

          -  Primary breast cancer (TNM stage = T1-3, N0-2, M0)

          -  Primary surgery

          -  Written informed consent

        Exclusion criteria:

          -  Metastatic breast cancer

          -  Other than primary surgery (recurrence, reconstruction)

          -  Pre-operative chemotherapy or radiotherapy

          -  Auto-immune disease, HIV, other active cancer, age&gt;85, ASA IV or V

          -  Concomitant regional anesthesia

          -  Chronic opioids medication

          -  Any systemic immunosuppressive therapy

          -  Known hypersensitivity or suspected allergy to propofol, soya or egg proteins

          -  Known hypersensitivity to volatile anesthetics (malignant hyperthermia)

          -  Pregnancy

          -  Breast feeding

          -  Non German-speaking patients

          -  Enrollment in any other clinical trial during the course of this trial, 30 days prior
             to its beginning or 30 days after its completion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Institute of Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice Beck Schimmer, Prof MD</last_name>
    <email>beatrice.beck@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schläpfer, MD</last_name>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Institute of Anesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Beck-Schimmer, Prof MD</last_name>
      <email>beatrice.beck@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Frédérique Hovaguimian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Physicians for Anesthesia and Intensive Care Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Seeberger, Prof MD</last_name>
      <email>manfred.seeberger@hirslanden.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rölli Urs, MD</last_name>
      <email>urs.roelli@hirslanden.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

